JP2024508672A - 新規抗ｃｄ２４抗体 - Google Patents

新規抗ｃｄ２４抗体 Download PDF

Info

Publication number
JP2024508672A
JP2024508672A JP2023547592A JP2023547592A JP2024508672A JP 2024508672 A JP2024508672 A JP 2024508672A JP 2023547592 A JP2023547592 A JP 2023547592A JP 2023547592 A JP2023547592 A JP 2023547592A JP 2024508672 A JP2024508672 A JP 2024508672A
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508672A5 (enExample
Inventor
チェン，ペン
ホウ，ビン
デン，ミン
リウ，ユン
ルオ，ジアメイ
ユーウェン，ホイ
シャン，ボー
メイ，ジェイ
Original Assignee
アンテンジーン バイオロジクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンテンジーン バイオロジクス リミテッド filed Critical アンテンジーン バイオロジクス リミテッド
Publication of JP2024508672A publication Critical patent/JP2024508672A/ja
Publication of JP2024508672A5 publication Critical patent/JP2024508672A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023547592A 2021-02-08 2022-02-08 新規抗ｃｄ２４抗体 Pending JP2024508672A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/076075 2021-02-08
CN2021076075 2021-02-08
CN202210088172 2022-01-25
CN202210088172.3 2022-01-25
PCT/US2022/015711 WO2022170280A2 (en) 2021-02-08 2022-02-08 Novel anti-cd24 antibodies

Publications (2)

Publication Number Publication Date
JP2024508672A true JP2024508672A (ja) 2024-02-28
JP2024508672A5 JP2024508672A5 (enExample) 2025-02-18

Family

ID=82741874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547592A Pending JP2024508672A (ja) 2021-02-08 2022-02-08 新規抗ｃｄ２４抗体

Country Status (11)

Country Link
US (1) US20240052052A1 (enExample)
EP (1) EP4288099A4 (enExample)
JP (1) JP2024508672A (enExample)
KR (1) KR20230143177A (enExample)
CN (1) CN117412770A (enExample)
AU (1) AU2022217072A1 (enExample)
CA (1) CA3210934A1 (enExample)
CO (1) CO2023011463A2 (enExample)
IL (1) IL304898A (enExample)
MX (1) MX2023009238A (enExample)
WO (1) WO2022170280A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121311506A (zh) * 2023-06-09 2026-01-09 天境生物科技(上海)有限公司 抗-cd24抗体及其用途
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
TW202535944A (zh) * 2023-11-08 2025-09-16 美商飛斯特醫療公司 Ｃｄ２４抗體
WO2025128830A1 (en) * 2023-12-12 2025-06-19 The Methodist Hospital Therapeutic lilrb regulation for treating neurological disorders
AU2024402617A1 (en) * 2023-12-19 2026-05-14 Pentixapharm Ag Antibodies against cd24
WO2025159754A1 (en) * 2024-01-25 2025-07-31 China Medical University Therapeutic cd24 humanized monoclonal antibodies and anti-tumor translational use
WO2025218729A1 (en) * 2024-04-17 2025-10-23 TJ Biopharma (Shanghai) Co., Ltd. Multifunctional molecules targeting cd24
CN119161485B (zh) * 2024-10-29 2026-03-24 上海中医药大学附属曙光医院 靶向GFRα3的抗体及其制备方法和在抗癌中的应用
WO2026117619A1 (en) * 2024-11-26 2026-06-04 Pheast Therapeutics, Inc. Cd24-binding antibodies
WO2026130747A1 (en) * 2024-12-19 2026-06-25 Pentixapharm Ag Antibodies against cd24

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502048A (ja) * 2014-01-08 2017-01-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
JP2017510251A (ja) * 2014-03-11 2017-04-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
WO2019222082A1 (en) * 2018-05-14 2019-11-21 Oncoimmune, Inc. Anti-cd24 compositions and uses thereof
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
WO2020261280A1 (en) * 2019-06-25 2020-12-30 Ichilov Tech Ltd. Anti-cd24 antibody and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080002341A (ko) * 2006-06-30 2008-01-04 재단법인서울대학교산학협력재단 Ｃｄ２４를 표적으로 하는 암 억제방법
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途
WO2015200522A2 (en) * 2014-06-25 2015-12-30 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502048A (ja) * 2014-01-08 2017-01-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
JP2017510251A (ja) * 2014-03-11 2017-04-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
WO2019222082A1 (en) * 2018-05-14 2019-11-21 Oncoimmune, Inc. Anti-cd24 compositions and uses thereof
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
WO2020261280A1 (en) * 2019-06-25 2020-12-30 Ichilov Tech Ltd. Anti-cd24 antibody and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXP. HEMATOL., vol. 14, JPN6026002192, 1986, pages 850 - 855, ISSN: 0005781709 *
LABORATORY INVESTIGATION, vol. 90, JPN6026002191, 2010, pages 1102 - 1116, ISSN: 0005912784 *

Also Published As

Publication number Publication date
AU2022217072A9 (en) 2024-01-18
TW202241956A (zh) 2022-11-01
EP4288099A2 (en) 2023-12-13
CO2023011463A2 (es) 2023-09-18
CA3210934A1 (en) 2022-08-11
US20240052052A1 (en) 2024-02-15
KR20230143177A (ko) 2023-10-11
WO2022170280A3 (en) 2022-09-09
IL304898A (en) 2023-10-01
AU2022217072A1 (en) 2023-10-05
EP4288099A4 (en) 2025-09-17
WO2022170280A2 (en) 2022-08-11
MX2023009238A (es) 2023-08-16
CN117412770A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
JP7737193B2 (ja) 新規抗ＣＤ３ε抗体
US20240052052A1 (en) Novel anti-cd24 antibodies
CN112867507B (zh) 新型抗sirpa抗体
WO2019179391A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
JP2024521045A (ja) 新規抗ｃｄ２７６抗体およびその使用
US20250270315A1 (en) Novel anti-sirpa antibodies
KR20250021334A (ko) 신규 항-gprc5d 항체, gprc5d와 cd3에 결합하는 이중특이적 항원 결합 분자, 및 이들의 용도
WO2019179422A1 (en) Novel bispecific pd-1/lag-3 antibody molecules
WO2019179421A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
US12486325B2 (en) Anti-CD3epsilon antibodies
EP4217396A1 (en) Novel anti-claudin18 antibodies
KR20240039005A (ko) 신규 다중-특이적 분자
WO2024099295A1 (en) Novel multi-specific antibodies and uses thereof
EA052500B1 (ru) Новые антитела против cd24
TW202317618A (zh) 新型抗ｃｄ２７６抗體及其用途
HK40106257A (zh) 新型抗sirpa抗体
WO2024131956A1 (zh) 靶向gprc5d的多特异性多肽复合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260721